RESPIRATORY SYNCYTIAL VIRUS
Clinical trials for RESPIRATORY SYNCYTIAL VIRUS explained in plain language.
Never miss a new study
Get alerted when new RESPIRATORY SYNCYTIAL VIRUS trials appear
Sign up with your email to follow new studies for RESPIRATORY SYNCYTIAL VIRUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
One shot, three shields? moderna tests RSV vaccine alongside flu and COVID boosters
⭐️ VACCINE ⭐️ CompletedThis study tested a new mRNA vaccine, mRNA-1345, designed to protect against Respiratory Syncytial Virus (RSV) in adults aged 50 and older. Researchers wanted to see if it was safe and effective when given by itself, or at the same time as a seasonal flu shot or a COVID-19 booste…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 03, 2026 22:56 UTC
-
New RSV shot for seniors put to the test in major safety trial
⭐️ VACCINE ⭐️ CompletedThis study tested a new vaccine designed to protect older adults from Respiratory Syncytial Virus (RSV). Researchers compared the vaccine to a placebo (a dummy shot) in 378 healthy Korean adults aged 60 and older to check for side effects and measure the body's immune response. P…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 03, 2026 14:43 UTC
-
Moderna tests Four-in-One mRNA vaccine cocktail in groundbreaking safety trial
⭐️ VACCINE ⭐️ CompletedThis study tested the safety and immune response of several Moderna mRNA vaccines designed to protect against four different viruses: COVID-19, seasonal flu, respiratory syncytial virus (RSV), and cytomegalovirus (CMV). It involved 308 healthy adults aged 18 to 75. The main goal …
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 03, 2026 14:41 UTC
-
Massive infant study tests One-Shot shield against dangerous RSV
Prevention CompletedThis study tested how well a single antibody shot (nirsevimab) protects infants from serious Respiratory Syncytial Virus (RSV) infections during their first RSV season. It involved nearly 50,000 infants to see if the shot reduced doctor visits, emergency room trips, and hospitali…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Prevention
Last updated Apr 02, 2026 14:56 UTC